The DNAJB2 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited mixed population of A2780 human epithelial ovarian carcinoma cells harboring targeted disruption of the DNAJB2 gene. As a polyclonal knockout pool, this product eliminates functional DNAJB2 expression across a genetically diverse cell population, providing a robust loss-of-function system for investigating DNAJB2-dependent pathways in ovarian cancer biology. CRISPR/Cas9-mediated gene ablation in these cells creates a reliable model to study co-chaperone function without relying on single-cell clone artifacts, enabling broader assessment of phenotypic consequences.
The A2780 cell line is a well-established human ovarian carcinoma model originally derived from an untreated patient, widely utilized in cancer research for studying drug sensitivity, apoptosis, and tumor progression. Its epithelial origin and retention of key signaling pathways make it particularly suitable for examining mechanisms of chemoresistance and stress adaptation. A2780 cells exhibit characteristic p53 functionality and express components of the ubiquitin-proteasome system, rendering them an ideal host for interrogating protein quality control networks.
DNAJB2 encodes a member of the Hsp40 co-chaperone family that specifically partners with Hsp70 (HSPA1A) to modulate ATPase activity and client protein processing. It functions as a critical adaptor in the ubiquitin-proteasome system by recruiting Hsp70-bound substrates to E3 ubiquitin ligases such as CHIP (STUB1), thereby targeting misfolded or aggregated proteins for proteasomal degradation. DNAJB2 is transcriptionally regulated by HSF1 in response to heat shock, ER stress, and oncogenic stress, and its expression influences the fate of diverse clients including p53 and other apoptosis regulators. The DNAJB2-Hsp70-CHIP axis is central to protein homeostasis, and disruption of this complex can lead to accumulation of proteotoxic species and altered cellular stress responses.
In the A2780 ovarian cancer context, DNAJB2 knockout provides a powerful tool to dissect the role of chaperone-mediated proteostasis in malignant transformation and therapy resistance. Ovarian carcinomas frequently encounter proteotoxic stress due to genomic instability and aberrant signaling, and reliance on the heat shock response for survival makes them potentially vulnerable to disturbances in the DNAJB2-dependent quality control network. Ablation of DNAJB2 in these cells may impair handling of misfolded proteins, alter apoptosis thresholds, and modify sensitivity to chemotherapeutic agents, thus offering insights into novel therapeutic strategies targeting the ubiquitin-proteasome system.
Researchers can employ this polyclonal knockout model in a wide array of functional assays. Western blotting and RT-qPCR confirm DNAJB2 ablation and assess downstream effectors such as Hsp70, CHIP, and proteasome subunits. Co-immunoprecipitation and immunofluorescence elucidate protein interactions and subcellular localization. Flow cytometry with Annexin V/PI staining monitors apoptosis, while MTT assays quantify cell proliferation. Migration and invasion assays evaluate metastatic potential, and fluorogenic substrate-based assays measure proteasome activity. These applications make the DNAJB2 Knockout A2780 Polyclonal Cells an essential resource for proteostasis, oncology, and drug discovery research. For further information, please contact Ascent Research.
